Alan C. Moss MD
85 E. Concord St | (617) 638-6116
Alan Moss, MD, FACG, AGAF, FEBG, FRCPI is a clinician-scientist with an interest in Crohn's disease and Ulcerative Colitis (Inflammatory Bowel Disease, IBD). His clinical expertise is in management of IBD, and he is Director of the Crohn's & Colitis Program at Boston Medical Center. His research interests include microbial therapeutics, mucosal immunology and clinical outcomes. He has held grant funding from NIDDK, AGA, Helmsley Charitable Trust, and the Crohn's & Colitis Foundation. He has published over 120 research papers (h-index 28), including many cited in national and international practice guidelines. Dr Moss has held positions as Deputy-Editor of Crohn's & Colitis 360, and as Associate Editor for Journal of Crohn’s & Colitis (ECCO), Frontline Gastroenterology (BMJ) and the World Journal of Gastroenterology. He has served on the Nominating Committee of the IBD section of AGA, and the Professional Education and National Scientific Advisory Committee for the Crohn's & Colitis Foundation. He is a reviewer for national and international research bodies, including the NIDDK and European Research Council.
Syal G, Serrano M, Jain A, Cohen BL, Rieder F, Stone C, Abraham B, Hudesman D, Malter L, McCabe R, Holubar S, Afzali A, Cheifetz AS, Gaidos JKJ, Moss AC. Health Maintenance Consensus for Adults With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2021 Jul 19. PMID: 34279600.Published on 6/9/2021
Ayyar KK, Moss AC. Exosomes in Intestinal Inflammation. Front Pharmacol. 2021; 12:658505. PMID: 34177577.Published on 1/19/2021
Osterman MT, Scott FI, Fogt FF, Gilroy ED, Parrott S, Galanko J, Cross R, Moss A, Herfarth HH, Higgins PDR. Endoscopic and Histological Assessment, Correlation, and Relapse in Clinically Quiescent Ulcerative Colitis (MARQUEE). Inflamm Bowel Dis. 2021 01 19; 27(2):207-214. PMID: 32170946.Published on 11/18/2020
Harshe RP, Xie A, Vuerich M, Frank LA, Gromova B, Zhang H, Robles RJ, Mukherjee S, Csizmadia E, Kokkotou E, Cheifetz AS, Moss AC, Kota SK, Robson SC, Longhi MS. Endogenous antisense RNA curbs CD39 expression in Crohn's disease. Nat Commun. 2020 11 18; 11(1):5894. PMID: 33208731.Published on 9/25/2020
Chibbar R, Moss AC. Mesalamine in the Initial Therapy of Ulcerative Colitis. Gastroenterol Clin North Am. 2020 12; 49(4):689-704. PMID: 33121689.Published on 9/1/2020
Bhat S, Farraye FA, Moss AC. Impact of Clinical Pharmacists in Inflammatory Bowel Disease Centers During the COVID-19 Pandemic. Am J Gastroenterol. 2020 09; 115(9):1532-1533. PMID: 32694291.Published on 8/20/2020
Cohen BL, Gallinger ZR, Ha C, Holubar SD, Hou JK, Kinnucan J, Mahadevan U, Moss AC, Raffals LE, Regueiro M, Szigethy E, Wolf D, Dubinsky MC, Patel A, Shah BJ, Ehrlich OG, Hanauer SB. Development of Entrustable Professional Activities for Advanced Inflammatory Bowel Disease Fellowship Training in the United States. Inflamm Bowel Dis. 2020 08 20; 26(9):1291-1305. PMID: 32820340.Published on 7/9/2020
Robles RJ, Mukherjee S, Vuerich M, Xie A, Harshe R, Cowan PJ, Csizmadia E, Wu Y, Moss AC, Chen R, Robson SC, Longhi MS. Modulation of CD39 and Exogenous APT102 Correct Immune Dysfunction in Experimental Colitis and Crohn's Disease. J Crohns Colitis. 2020 Jul 09; 14(6):818-830. PMID: 31693091.Published on 6/24/2020
Segal JP, Moss AC. Implications of recurrent SARS-CoV-2 outbreaks for IBD management. Frontline Gastroenterol. 2021; 12(4):316-321. PMID: 34249317.Published on 6/10/2020
Bai A, Moss A, Rothweiler S, Longhi MS, Wu Y, Junger WG, Robson SC. Author Correction: NADH oxidase-dependent CD39 expression by CD8+ T cells modulates interferon gamma responses via generation of adenosine. Nat Commun. 2020 06 10; 11(1):3036. PMID: 32522986.
Published on 6/27/2020View full list of 1 media mentions.